{"id":"eszopiclone-3-mg-non-elderly","safety":{"commonSideEffects":[{"rate":"15-21%","effect":"Headache"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"10-14%","effect":"Somnolence"},{"rate":"8-17%","effect":"Unpleasant taste"},{"rate":"5-10%","effect":"Anxiety"},{"rate":"5-7%","effect":"Dry mouth"},{"rate":"1-3%","effect":"Hallucinations"},{"rate":"<1%","effect":"Complex sleep behaviors"}]},"_chembl":{"chemblId":"CHEMBL1522","moleculeType":"Small molecule","molecularWeight":"388.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. By enhancing the effect of the inhibitory neurotransmitter GABA, it increases chloride ion influx into neurons, leading to hyperpolarization and reduced neuronal firing. This results in sedation and sleep initiation and maintenance.","oneSentence":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:24.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep initiation and maintenance) in non-elderly adults"}]},"trialDetails":[{"nctId":"NCT02455271","phase":"","title":"Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":438},{"nctId":"NCT02452684","phase":"","title":"Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":4876},{"nctId":"NCT00770692","phase":"PHASE3","title":"A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Insomnia","enrollment":369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SEP-190"],"phase":"phase_3","status":"active","brandName":"Eszopiclone 3 mg- Non-elderly","genericName":"Eszopiclone 3 mg- Non-elderly","companyName":"Eisai Co., Ltd.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep. Used for Insomnia (sleep initiation and maintenance) in non-elderly adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}